5.69 USD
+0.12
2.15%
At close Dec 13, 4:00 PM EST
After hours
5.63
-0.06
1.05%
1 day
2.15%
5 days
-1.04%
1 month
-18.60%
3 months
7.97%
6 months
-29.93%
Year to date
-32.50%
1 year
-24.93%
5 years
-27.52%
10 years
-27.52%
 

About: LifeMD Inc is a direct-to-patient telehealth company that provides a smarter, cost-effective, and more convenient way of accessing comprehensive, virtual healthcare. Its telehealth platform seamlessly integrates a clinician-centric electronic medical record (EMR) system, proprietary algorithms for case-load balancing and scheduling, customer relationship management functionality, remote and in-home lab testing, and digital prescription capabilities, patient-provider audio/video interfacing, cloud pharmacy fulfillment, and more. In addition to telehealth offerings, the company sells nutritional supplements and other over-the-counter products. The company has two operating segments: Telehealth and WorkSimpli. The company generates the majority of its revenue from the Telehealth segment.

Employees: 232

0
Funds holding %
of 6,805 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

96% more call options, than puts

Call options by funds: $828K | Put options by funds: $423K

17% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 29

0.75% less ownership

Funds ownership: 40.57% [Q2] → 39.82% (-0.75%) [Q3]

3% less funds holding

Funds holding: 103 [Q2] → 100 (-3) [Q3]

13% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 23

22% less capital invested

Capital invested by funds: $116M [Q2] → $89.9M (-$25.7M) [Q3]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$7
23%
upside
Avg. target
$11.50
102%
upside
High target
$15
164%
upside

4 analyst ratings

positive
75%
neutral
25%
negative
0%
Lake Street
Brooks O'Neil
50% 1-year accuracy
5 / 10 met price target
111%upside
$12
Buy
Initiated
10 Dec 2024
Mizuho
Steven Valiquette
40% 1-year accuracy
2 / 5 met price target
23%upside
$7
Neutral
Initiated
4 Dec 2024
HC Wainwright & Co.
Yi Chen
42% 1-year accuracy
65 / 153 met price target
111%upside
$12
Buy
Reiterated
11 Nov 2024
Cantor Fitzgerald
Sarah James
26% 1-year accuracy
34 / 131 met price target
164%upside
$15
Overweight
Reiterated
20 Sept 2024

Financial journalist opinion

Positive
CNBC Television
2 weeks ago
Health care stocks jump on Trump's nominee for FDA head
CNBC's Angelica Peebles joins 'Fast Money' to talk president-elect Trump's pick for FDA head.
Health care stocks jump on Trump's nominee for FDA head
Neutral
Seeking Alpha
1 month ago
LifeMD, Inc. (LFMD) Q3 2024 Earnings Call Transcript
LifeMD, Inc. (NASDAQ:LFMD ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Justin Schreiber – Chairman and Chief Executive Officer Marc Benathen – Chief Financial Officer Conference Call Participants David Larsen - BTIG Sarah James - Cantor Fitzgerald Kyle Bauser - B. Riley Securities Steve Dechert - KeyBanc Eduardo Martinez-Montes - H.C.
LifeMD, Inc. (LFMD) Q3 2024 Earnings Call Transcript
Negative
Zacks Investment Research
1 month ago
LifeMD, Inc. (LFMD) Reports Q3 Loss, Lags Revenue Estimates
LifeMD, Inc. (LFMD) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.20 per share a year ago.
LifeMD, Inc. (LFMD) Reports Q3 Loss, Lags Revenue Estimates
Neutral
GlobeNewsWire
1 month ago
LifeMD Reports Third Quarter 2024 Results
Total revenues increased 38% year-over-year to $53.4 million with telehealth revenue up 65% Record gross margin of 90.6%, up 300 basis points from the year-ago period Adjusted EBITDA increased 33% to $3.7 million Telehealth adjusted EBITDA of $2.5 million, a 200% sequential increase versus the second quarter Cash of $37.6 million as of September 30, 2024 Generated $6.2 million of cash flow from operations in the third quarter and positive net cash flow in each of the last four quarters Conference call begins at 4:30 p.m. Eastern time today NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today reported financial results for the three and nine months ended September 30, 2024.
LifeMD Reports Third Quarter 2024 Results
Positive
Zacks Investment Research
1 month ago
LifeMD Shares Decline Even After the Launch of Testosterone Therapy
LFMD expands its men's health services with TestoRx, offering convenient testosterone therapy and alternative treatments for low testosterone via telehealth.
LifeMD Shares Decline Even After the Launch of Testosterone Therapy
Neutral
GlobeNewsWire
2 months ago
LifeMD® Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share.
LifeMD® Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
Positive
Seeking Alpha
3 months ago
LifeMD: Selling WorkSimpli Could Be A Catalyst
LifeMD's Q2 2024 earnings were mixed, with management failing to monetize the non-core WorkSimpli asset, leading me to assign it no value. Despite management's over-promising, LifeMD's telehealth and GLP1 offerings show significant potential, with the stock priced at 14x forward EBITDA. I have revised my price target from $20 to $15 per share by summer 2025, due to management's credibility issues and uncertainties in GLP1 prospects.
LifeMD: Selling WorkSimpli Could Be A Catalyst
Neutral
GlobeNewsWire
3 months ago
LifeMD to Participate in Three Investor Conferences During September
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor conferences during the month of September:
LifeMD to Participate in Three Investor Conferences During September
Neutral
Seeking Alpha
4 months ago
LifeMD, Inc. (LFMD) Q2 2024 Earnings Call Transcript
LifeMD, Inc. (NASDAQ:LFMD ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Justin Schreiber – Chairman and Chief Executive Officer Marc Benathen – Chief Financial Officer Conference Call Participants David Larsen – BTIG Steve Dechert – KeyBanc William Wood – B. Riley Securities Sarah James – Cantor Yi Chen – H.C.
LifeMD, Inc. (LFMD) Q2 2024 Earnings Call Transcript
Negative
Zacks Investment Research
4 months ago
LifeMD, Inc. (LFMD) Reports Q2 Loss, Tops Revenue Estimates
LifeMD, Inc. (LFMD) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.23 per share a year ago.
LifeMD, Inc. (LFMD) Reports Q2 Loss, Tops Revenue Estimates
Charts implemented using Lightweight Charts™